MARKET

NUVL

NUVL

Nuvalent, Inc.
NASDAQ
105.64
+3.19
+3.11%
After Hours: 105.64 0 0.00% 17:49 04/01 EDT
OPEN
103.51
PREV CLOSE
102.45
HIGH
106.90
LOW
102.47
VOLUME
1.01M
TURNOVER
--
52 WEEK HIGH
113.02
52 WEEK LOW
55.54
MARKET CAP
8.31B
P/E (TTM)
-18.0513
1D
5D
1M
3M
1Y
5Y
1D
Nuvalent (NUVL) Receives a Buy from Stifel Nicolaus
TipRanks · 1d ago
Nuvalent Chief Legal Officer Deborah Ann Miller disposes of $0.54 million common shares
Reuters · 2d ago
Nuvalent Price Target Announced at $116.00/Share by Wells Fargo
Dow Jones · 2d ago
Wells Fargo Initiates Coverage On Nuvalent with Overweight Rating, Announces Price Target of $116
Benzinga · 2d ago
NUVALENT, INC. <NUVL.O>: WELLS FARGO INITIATES COVERAGE WITH OVERWEIGHT RATING AND TARGET PRICE $116
Reuters · 2d ago
Nuvalent initiated with an Overweight at Wells Fargo
TipRanks · 2d ago
Weekly Report: what happened at NUVL last week (0323-0327)?
Weekly Report · 2d ago
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
Reuters · 2d ago
More
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.

Webull offers Nuvalent, Inc stock information, including NASDAQ: NUVL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NUVL stock methods without spending real money on the virtual paper trading platform.